CTLA4 and osteosarcoma: Our studies also showed that low-dose α-PD-L1 therapy alone normalized osteosarcoma-induced systemic immunodysregulation back to that of SH status without changing clinical outcome; however, a compensatory increase in the immunosuppressive marker CTLA-4 on CTLs was observed following PD-L1 blockade indicating a potential tumor escape mechanism.